Form 8-K - Current report:
SEC Accession No. 0001193125-26-333820
Filing Date
2026-08-05
Accepted
2026-08-05 07:05:06
Documents
13
Period of Report
2026-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d124829d8k.htm   iXBRL 8-K 25758
2 EX-99.1 d124829dex991.htm EX-99.1 86750
6 GRAPHIC g124829g0805035603233.jpg GRAPHIC 3549
  Complete submission text file 0001193125-26-333820.txt   241903

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20260805.xsd EX-101.SCH 3195
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20260805_lab.xml EX-101.LAB 17233
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20260805_pre.xml EX-101.PRE 10822
16 EXTRACTED XBRL INSTANCE DOCUMENT d124829d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 261241292
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)